Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics adds Anna Greka as director, board grows to seven

Neutral Impact 2 of 5 leadership Written later

Ovid Therapeutics said its board approved expanding the board to seven directors and appointing Dr. Anna Greka as a Class III director, effective June 15, 2026. Dr. Greka will also join the Compensation Committee and Science and Technology Committee, and will receive director pay under the company's existing policy.

Key points

  • Board approved the appointment on May 29, 2026, effective June 15, 2026, with a term expiring at the 2029 annual meeting.
  • Board size increases to seven directors effective June 15, 2026.
  • Dr. Greka, age 50, is a Professor of Medicine at Harvard Medical School and Mass General Brigham, and holds several Broad Institute roles.
  • Dr. Greka signed the company's standard indemnification agreement.

The filing

CompanyOvid Therapeutics Inc. (OVID)
Form8-K, current report
Filed with the SECJun 3, 2026, 7:03 AM ET
Accession number0001628280-26-040038

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.